1. Benzimidazole-based compounds kill Mycobacterium tuberculosis
- Author
-
Thulasi Warrier, Carl Nathan, David Little, Selin Somersan Karakaya, Purong Zheng, Xiaoyong Guo, Yao Ma, Yaling Gong, Gang Liu, Maneesh Pingle, Xiuju Jiang, Julia Roberts, and Ben Gold
- Subjects
Benzimidazole ,Tuberculosis ,medicine.drug_class ,Antibiotics ,Antitubercular Agents ,Microbial Sensitivity Tests ,Microbiology ,Mycobacterium tuberculosis ,Structure-Activity Relationship ,chemistry.chemical_compound ,Drug Discovery ,medicine ,Humans ,Potency ,Cytotoxicity ,Nitrofuran ,Cells, Cultured ,Pharmacology ,biology ,Chemistry ,Macrophages ,Organic Chemistry ,General Medicine ,biology.organism_classification ,medicine.disease ,SOS chromotest ,Drug Design ,Benzimidazoles - Abstract
Tuberculosis remains one of the deadliest infectious diseases, killing 1.4 million people annually and showing a rapid increase in cases resistant to multiple drugs. New antibiotics against tuberculosis are urgently needed. Here we describe the design, synthesis and structure-activity relationships of a series of benzimidazole-based compounds with activity against Mycobacterium tuberculosis (Mtb) in a replicating state, a physiologically-induced non-replicating state, or both. Compounds 49, 67, 68, 69, 70, and 72, which shared a 5-nitrofuranyl moiety, exhibited high potency and acceptable selectivity indices (SI). As illustrated by compound 70 (MIC900.049 μg/mL, SI512), the 5-nitrofuranyl group was compatible with minimal cytotoxicity and good intra-macrophage killing, although it lacked non-replicating activity when assessed by CFU assays. Compound 70 had low mutagenic potential by SOS Chromotest assay, making this class of compounds good candidates for further evaluation and target identification.
- Published
- 2014
- Full Text
- View/download PDF